1. Br J Cancer. 2011 Apr 12;104(8):1356-61. doi: 10.1038/bjc.2011.91. Epub 2011
Mar  22.

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation 
carriers. Results from the consortium of investigators of modifiers of 
BRCA1/BRCA2.

Osorio A(1), Milne RL, Alonso R, Pita G, Peterlongo P, Teulé A, Nathanson KL, 
Domchek SM, Rebbeck T, Lasa A, Konstantopoulou I, Hogervorst FB, Verhoef S, van 
Dooren MF, Jager A, Ausems MG, Aalfs CM, van Asperen CJ, Vreeswijk M, Waisfisz 
Q, Van Roozendaal CE, Ligtenberg MJ; HEBON; EMBRACE; Easton DF, Peock S, Cook M, 
Oliver CT, Frost D, Curzon B, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, 
Adlard J, Eccles D, Ong KR, Douglas F, Downing S, Brewer C, Walker L, Nevanlinna 
H, Aittomäki K, Couch FJ, Fredericksen Z, Lindor NM, Godwin A, Isaacs C, Caligo 
MA, Loman N, Jernström H, Barbany-Bustinza G, Liljegren A, Ehrencrona H, 
Stenmark-Askmalm M; Sw E-BRCA; Feliubadaló L, Manoukian S, Peissel B, Zaffaroni 
D, Bonanni B, Fortuzzi S, Johannsson OT, Chenevix-Trench G, Chen XC, Beesley J, 
Spurdle AB; kConFab; Sinilnikova OM, Healey S, McGuffog L, Antoniou AC, Brunet 
J, Radice P, Benítez J; CIMBA.

Collaborators: Hogervorst FB, Verhoef S, Verheus M, van 't Veer LJ, van Leeuwen 
FE, Rookus MA, Collée M, van den Ouweland AM, Jager A, Hooning MJ, 
Tilanus-Linthorst MM, Seynaeve C, van Asperen CJ, Wijnen JT, Vreeswijk MP, 
Tollenaar RA, Devilee P, Ligtenberg MJ, Hoogerbrugge N, Ausems MG, van der Luijt 
RB, Aalfs CM, van Os TA, Gille JJ, Waisfisz Q, Meijers-Heijboer HE, Gomez-Garcia 
EB, van Roozendaal CE, Blok MJ, Caanen B, Oosterwijk JC, van der Hout AH, 
Mourits MJ, Vasen HF, Peock S, Cook M, Oliver C, Frost D, Miedzybrodzka Z, 
Gregory H, Morrison P, Jeffers L, Cole T, McKeown C, Ong KR, Hoffman J, 
Donaldson A, Paterson J, Downing S, Taylor A, Murray A, Rogers MT, McCann E, 
Kennedy MJ, Barton D, East S, Porteous M, Drummond S, Brewer C, Kivuva E, Searle 
A, Goodman S, Hill K, Davidson R, Bradshaw N, Snadden L, Longmuir M, Watt C, 
Gibson S, Izatt L, Jacobs C, Langman C, Whaite A, Dorkins H, Barwell J, Adlard 
J, Chu C, Miller J, Ellis I, Evans DG, Lalloo F, Taylor J, Side L, Male A, 
Berlin C, Eason J, Collier R, Douglas F, Claber O, Walker L, McLeod D, Halliday 
D, Durell S, Stayner B, Eeles R, Shanley S, Rahman N, Houlston R, Bancroft E, 
D'Mello L, Page E, Ardern-Jones A, Kohut K, Wiggins J, Castro E, Mitra A, 
Robertson L, Cook J, Quarrell O, Bardsley C, Hodgson S, Goff S, Brice G, 
Winchester L, Eddy C, Tripathi V, Attard V, Eccles D, Lucassen A, Crawford G, 
McBride D, Smalley S, Godwin AK, Karlsson P, Nordling M, Bergman A, Einbeigi Z, 
Stenmark- Askmalm M, Liedgren S, Borg A, Loman N, Olsson H, Kristoffersson U, 
Jernström H, Harbst K, Henriksson K, Lindblom A, Arver B, Wachenfeldt Av, 
Liljegren A, Barbany-Bustinza G, Rantala J, Melin B, Grönberg H, Stattin EL, 
Emanuelsson M, Ehrencrona H, Rosenquist Brandell R, Dahl N.

Author information:
(1)Human Genetics Group, Spanish National Cancer Centre, C/Melchor Fernández 
Almagro 3, 28029 Madrid, Spain. aosorio@cnio.es

BACKGROUND: Single-nucleotide polymorphisms (SNPs) in genes involved in DNA 
repair are good candidates to be tested as phenotypic modifiers for carriers of 
mutations in the high-risk susceptibility genes BRCA1 and BRCA2. The base 
excision repair (BER) pathway could be particularly interesting given the 
relation of synthetic lethality that exists between one of the components of the 
pathway, PARP1, and both BRCA1 and BRCA2. In this study, we have evaluated the 
XRCC1 gene that participates in the BER pathway, as phenotypic modifier of BRCA1 
and BRCA2.
METHODS: Three common SNPs in the gene, c.-77C>T (rs3213245) p.Arg280His 
(rs25489) and p.Gln399Arg (rs25487) were analysed in a series of 701 BRCA1 and 
576 BRCA2 mutation carriers.
RESULTS: An association was observed between p.Arg280His-rs25489 and breast 
cancer risk for BRCA2 mutation carriers, with rare homozygotes at increased risk 
relative to common homozygotes (hazard ratio: 22.3, 95% confidence interval: 
14.3-34, P<0.001). This association was further tested in a second series of 
4480 BRCA1 and 3016 BRCA2 mutation carriers from the Consortium of Investigators 
of Modifiers of BRCA1 and BRCA2.
CONCLUSIONS AND INTERPRETATION: No evidence of association was found when the 
larger series was analysed which lead us to conclude that none of the three SNPs 
are significant modifiers of breast cancer risk for mutation carriers.

DOI: 10.1038/bjc.2011.91
PMCID: PMC3078599
PMID: 21427728 [Indexed for MEDLINE]